SCHEMBL25344307

SCHEMBL25344307

FC(F)(F)COc1ccc2cn[nH]c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.57
FGFR1 P11362 7/20 0.48
FGFR2 P21802 5/20 0.48
FGFR3 P22607 2/20 0.48
DYRK1A Q13627 3/20 0.45
NOS1 P29475 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
PKM P14618 1/20 0.45
HTT P42858 1/20 0.45
CYP17A1 P05093 2/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
TRPA1 O75762 1/20 0.42
DRD2 P14416 2/20 0.41
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40
PDPK1 O15530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28814958 0.88 MEN1 (0.48) METAP2NOS1KDM4EMEN1MAPT
SCHEMBL28738120 0.82 SYK (0.51) METAP2FGFR1FGFR2FGFR3DYRK1A
SCHEMBL10601519 0.79 METAP2 (0.57) METAP2FGFR1FGFR2FGFR3DYRK1A
SCHEMBL16711152 0.79 FGFR2 (0.71) METAP2FGFR1FGFR2FGFR3DYRK1A
SCHEMBL31243810 0.79 METAP2 (0.57) METAP2FGFR1FGFR2FGFR3DYRK1A
Trifluoroacetic Acid SCHEMBL20974298 0.76 PTPN7 (0.48) METAP2FGFR1FGFR2FGFR3KDM4E
SCHEMBL30536621 0.76 FGFR1 (0.52) METAP2FGFR1FGFR2FGFR3DYRK1A
SCHEMBL26660931 0.76 FGFR1 (0.52) METAP2FGFR1FGFR2FGFR3DYRK1A
SCHEMBL25346085 0.76 METAP2 (0.46) METAP2FGFR1FGFR2DYRK1ANOS1
SCHEMBL4978879 0.75 FGFR1 (0.51) METAP2FGFR1FGFR2FGFR3DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
WO-2022015938-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 METAP2 3095/4885FGFR1 2339/4885FGFR2 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.